#Taiwan #Taipei #Diabetic Foot Ulcers #Energenesis #ENERGI-F703DFU

Energenesis Biomedical to Present Clinical Application of ENERGI-F703DFU at EWMA 2026

Energenesis Biomedical Co., Ltd. is poised to make a significant impact at the upcoming European Wound Management Association (EWMA) conference in Bremen, Germany, scheduled from May 5 to 7, 2026. The clinical-stage biopharmaceutical company is set to present their promising investigational drug candidate, ENERGI-F703DFU. This innovative therapy is designed to address diabetic foot ulcers (DFUs), a challenging condition that affects many patients worldwide.

Presentation Details

Energenesis's presentation, titled "ENERGI-F703DFU Gel: A Novel Topical Drug for the Treatment of Diabetic Foot Ulcers — Clinical Case Sharing", will take place on May 6, 2026, at 14:35 CEST. Attendees can expect to gain insights into the clinical application of ENERGI-F703DFU, including compelling case studies that highlight its efficacy in promoting wound closure and enhancing healing outcomes for patients suffering from chronic, non-healing diabetic foot ulcers.

Overview of ENERGI-F703DFU

ENERGI-F703DFU represents a potential breakthrough in the treatment of diabetic foot ulcers. This small-molecule topical gel works by restoring cellular energy pathways that are crucial for wound healing. By increasing intracellular ATP levels in epithelial cells at the wound site, the gel promotes cell regeneration and activates the body's intrinsic repair mechanisms.

Currently, ENERGI-F703DFU is undergoing Phase III clinical trials in both Taiwan and the United States (NCT05930210). The trials are focused on treating diabetic foot ulcers classified as Grade 1 and Grade 2 per the Wagner Grading System, targeting ulcers between 1.5 cm² and 25 cm² over a treatment span of 16 weeks. Previously, Phase II trials had shown promising results, with a remarkable 36.7% complete closure rate in the treatment group compared to just 9.1% in controls (P<0.05), prompting further investigation into its efficacy.

Addressing a Global Health Challenge

Diabetic foot ulcers present a substantial healthcare challenge globally, often resulting in serious complications such as infections, extended hospital stays, and even amputations. Despite advancements in treatment protocols, existing pharmaceutical options remain limited, highlighting the critical need for effective therapies like ENERGI-F703DFU that can significantly expedite wound healing and cellular regeneration.

Energenesis Biomedical is committed to transforming the landscape of treatment for chronic wounds through innovative solutions. The company aims to tackle major unmet medical needs across various therapeutic areas, with a focus on harnessing cellular energy restoration to activate healing processes in patients.

About Energenesis Biomedical

Founded to specialize in cellular energy restoration therapeutics, Energenesis Biomedical is at the forefront of developing cutting-edge treatments, including those for chronic wounds and neurodegenerative diseases. Their diverse pipeline includes:

• - ENERGI-F701: A tonic for alopecia (Phase II completed).
• - ENERGI-F703DFU: Gel specifically for diabetic foot ulcers (Phase III).
• - ENERGI-F703EB: Cream for epidermolysis bullosa, which has received FDA Orphan Drug and EMA orphan designations (Phase II ready).
• - ENERGI-F705PD: A tablet aimed at addressing Parkinson's disease, currently preparing for Phase II.

As Energenesis gears up for its presentation at EWMA 2026, the healthcare community eagerly anticipates the potential of ENERGI-F703DFU to change the standard of care for diabetic foot ulcers, providing hope to countless patients around the world.